ALK and non-small cell lung carcinoma: Overall, alectinib, brigatinib, or lorlatinib have become the first‐line regimens, whereas ceritinib is the “other recommended” option, and crizotinib is recommended as “useful in certain circumstances” in the NCCN guidelines (2022 v3) for ALK‐positive NSCLC.